| Autor: |
Atci MM; Department of Medical Oncology, University of Health Sciences, Professor Doctor Cemil Tascioglu Istanbul City Hospital, İstanbul, Turkey., Akagunduz B; Department of Medical Oncology, Erzincan Binali Yıldrıım University Medical School, Erzincan, Turkey., Demir M; Department of Medical Oncology, Erzurum Training and Research Hospital, Erzurum, Turkey., Arikan R; Department of Medical Oncology, Marmara University Medical School, Istanbul, Turkey., Ay S; Department of Medical Oncology, Istanbul Medeniyet University, Goztepe Education and Research Hospital, Istanbul, Turkey., Ozer M; Department of Internal Medicine, Capital Health Regional Medical Center, Trenton, United States., Ayhan M; Department of Medical Oncology, Kartal Lutfi Kırdar Research Hospital, Istanbul, Turkey., Cil I; Department of Medical Oncology, University of Health Sciences, Umranıye training and Research hospital, Istanbul, Turkey., Demir N; Department of Medical Oncology, Eskisehir Osmangazi University Medical School, Eskişehir., Ozyurt N; Department of Medical Oncology, Gıresun Research Hospital, Gıresun, Turkey., Karakaya G; Department of Medical Oncology, Mardın, Research Hospital, Mardın, Turkey., Cevik GT; Department of Medical Oncology, Usak Research Hospital, Usak, Turkey., Onder AH; Department of Medical Oncology, University of Health Sciences, Antalya training and Research hospital, Antalya, Turkey., Selvi O; Department of Medical Oncology, University of Health Sciences, Professor Doctor Cemil Tascioglu Istanbul City Hospital, İstanbul, Turkey., Sakin A; Department of Medical Oncology, University of Health Sciences, Professor Doctor Cemil Tascioglu Istanbul City Hospital, İstanbul, Turkey. |
| Abstrakt: |
The aim of this multicentre retrospective study was to compare the efficacy of adjuvant chemotherapy regimens both with and without oxaliplatin and tumor sidedness in stage IIB (pT4aN0) colon cancer patients. This study included patients with stage IIB colon cancer who underwent curative surgery and received adjuvant chemotherapy. The patients were divided into two groups (one with and one without oxaliplatin) to compare the overall survival (OS) in right- and left-sided tumors. The study population included 298 patients with stage IIB colon cancer (median age: 57) of whom 69.1% were male. Forty-four per cent of these patients (n = 131) were diagnosed with right-sided colon cancer. The median follow-up duration was 35.9 months. In the entire population, a median OS was not reached, and the five-year OS was 83%. The median disease-free survival (DFS) was 12 months. There was no significant difference in terms of the five-year OS between right- (82%) and left-sided (84%) colon tumors ( p = 0.67). In addition, the five-year OS of patients treated with and without oxaliplatin were 76% and 89%, respectively, and there was no statistically significant difference ( p = 0.23). The five-year OS of the patients treated with and without oxaliplatin were 83% and 96.5%, respectively, ( p = 0.8) in right-sided colon tumors, while it was 75% and 93% ( p = 0.06), respectively, in left-sided colon tumors. Tumor sidedness and the addition of oxaliplatin to adjuvant chemotherapy were not found to be associated with the OS in stage IIB colon cancer patients in our study. Further large prospective studies that also include MSI, RAS and BRAF status data are warranted in colon cancer patients. |
